Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitors of ABC drug transporters at the blood-brain barrier

a technology of abc drug and bloodbrain barrier, which is applied in the direction of heterocyclic compound active ingredients, biocide, animal husbandry, etc., can solve the problems of preventing the development of therapies for a wide variety of disorders, delivering these pharmaceutical substances to their active sites in the central nervous system, and affecting the development of therapies. , to achieve the effect of enhancing the efficacy of a non-opioid cns-active agent, reducing the efficacy rate rate ra

Inactive Publication Date: 2007-03-08
SHOENHARD GRANT L
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides methods and compositions for improving the efficacy of opioid and non-opioid CNS-active agents by inhibiting drug transporter proteins, such as PGP and MRP, that facilitate the efflux of such agents from the brain. The invention also provides methods for preventing or reversing tolerance to CNS-active agents and treating chronic pain without tolerance or dependence. The invention further provides methods of controlling chronic pain without tolerance or withdrawal by reducing efflux of CNS-active agents from the brain or increasing their concentration in the brain. The invention also provides methods of enhancing the efficacy of non-opioid CNS-active agents by co-administering them with an opioid receptor antagonist to reduce efflux of the agent from the brain and increase its concentration in the brain."

Problems solved by technology

For example, resistance modulators useful against P-glycoprotein are less effective in reversing MRP-mediated resistance.
However, delivering these pharmaceutical substances to their active sites in the central nervous system (CNS), particularly the brain, can be problematic due to the very limited permeability of the blood brain barrier, which discourages transport of many therapeutically active agents into the brain.
The ability of the blood brain barrier to protect the nervous system from exogenous substances has impeded the development of therapies for a wide variety of disorders and conditions of the central nervous system.
The blood brain barrier presents a particularly difficult obstacle to treating conditions in which the therapeutic agents must act upon sites within the central nervous system, particularly the brain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of ABC drug transporters at the blood-brain barrier
  • Inhibitors of ABC drug transporters at the blood-brain barrier
  • Inhibitors of ABC drug transporters at the blood-brain barrier

Examples

Experimental program
Comparison scheme
Effect test

example 1

Opioid Receptor Antagonists Inhibit Human PGP-Mediated Transport

[0067] Porcine kidney-derived, LLC-PK1, cells expressing human PGP cDNA (designated 15B-J) were cultured in 24 well Transwell™ culture inserts at 37° C. on an orbital shaker. Transport assays were conducted in 24 well Transwell™ culture inserts with Hanks Balanced Salt Solution (HBSS) buffered with the addition of 10 mM HEPES (pH 7.2).

[0068] The test substances, naloxone, naltrexone and nalmefene, were purchased from Sigma-Aldrich. Stock solutions of the compounds were made in DMSO, and dilutions of these in transport buffer were prepared for assay in the monolayers. The DMSO concentration (0.55%) was constant for all conditions within the experiment. All test substance and control drug solutions prepared in HBSS / HEPES buffer contained 0.55% DMSO.

[0069] The test substance was added to the donor and receiver chambers. Duplicate monolayers and thirteen test substance concentrations of 0.0001, 0.0003, 0.001, 0.003, 0.01...

example 2

6-β-Naltrexol Does Not Inhibit Human PGP-Mediated Transport

[0074] Porcine kidney-derived, LLC-PK1, cells expressing human PGP cDNA (designated 15B-J) were cultured in 24 well Transwell™ culture inserts at 37° C. on an orbital shaker. Transport assays were conducted in 24 well Transwell™ culture inserts with Hanks Balanced Salt Solution (HBSS) buffered with the addition of 10 mM HEPES (pH 7.2).

[0075] The test substance, 6-β-naltrexol, was provided by LC Resources, Inc. Stock solutions of the compounds were made in DMSO, and dilutions of these in transport buffer were prepared for assay in the monolayers. The DMSO concentration (0.55%) was constant for all conditions within the experiment. All test substance and control drug solutions prepared in HBSS / HEPES buffer contained 0.55% DMSO.

[0076] The test substance was added to the donor and receiver chambers. Duplicate monolayers and thirteen test substance concentrations of 0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10,...

example 3

Opioid Receptor Antagonists Inhibit PGP ATPase Activity

[0080] The test substances, naloxone, naltrexone and nalmefene, were purchased from Sigma-Aldrich. Stock solutions of the compounds were made in DMSO, and dilutions of these in transport buffer were prepared for assay in the monolayers. The DMSO concentration (0.55%) was constant for all conditions within the experiment. All test substance and control drug solutions prepared in HBSS / HEPES buffer contained 0.55% DMSO.

[0081] The test substances were incubated in the membranes and supplemented with MgATP, with and without sodium orthovanadate present. Orthovanadate inhibits PGP by trapping MgADP in the nucleotide binding site. Thus, the ATPase activity measured in the presence of orthovanadate represents non-PGP ATPase activity and was subtracted from the activity generated without orthovanadate to yield vanadate-sensitive ATPase activity.

[0082] ATPase assays were conducted in 96-well microtiter plates. A 0.06 ml reaction mixtur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
voltageaaaaaaaaaa
flow rateaaaaaaaaaa
Login to View More

Abstract

The present invention relates to inhibitors of drug transporters of the ABC protein superfamily, particularly transporters present at the blood brain barrier. ABC transporter inhibitors identified according to the invention increase brain concentrations of CNS-active agents. Such inhibitors increase the influx into the brain and / or reduce the efflux from the brain of such CNS-active agents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority of the following U.S. Patent Application Nos. 60 / 244,482, filed Oct. 30, 2000 (provisional); 60 / 245,110, filed Nov. 1, 2000 (provisional); and 60 / 245,235, filed Nov. 2, 2000 (provisional). The applications cited above are hereby incorporated herein by reference in their entirety to provide continuity of disclosure.INTRODUCTION Background [0002] ATP-binding cassette (ABC) proteins play a central role in living cells through their role in nutrient uptake, protein, drug and antibiotic secretion, osmoregulation, antigen presentation, signal transduction and others. The majority of ABC proteins have a translocation function either in import of substrates or secretion of cellular products or xenobiotics. [0003] The ATP-binding cassette (ABC) superfamily is one of the largest superfamilies known. With the multiplication of genome sequencing projects, new sequences appear every week in the GenBank database. Memb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/485A61K45/06
CPCA61K31/485A61K45/06A61K2300/00
Inventor SHOENHARD, GRANT L.
Owner SHOENHARD GRANT L
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com